Drug Approvals
Page 2 • 12 itemsTrack global drug approvals & regulatory decisions. Gain critical intelligence on new therapies, market access, and competitive landscapes for pharma BD.
PMDA SAKIGAKE Designation: Accelerating Innovation in Japan's Pharma Sector
The PMDA SAKIGAKE Designation is transforming Japan's pharmaceutical landscape, expediting the development of innovative drugs like XYZ for cancer treatment.
Claruvis Pharmaceutical's Retoxin Becomes World's First Approved Recombinant Botulinum Toxin Type A in China
China's NMPA approves Retoxin, the world's first recombinant botulinum toxin type A, marking a technological breakthrough in aesthetic medicine treatments.
PMDA SAKIGAKE Designation: Accelerating Rare Disease Therapy Approvals in Japan
The PMDA SAKIGAKE Designation fast-tracks the approval process for rare disease therapies, exemplified by XYZ Drug for ABC indication in Japan.
PMDA SAKIGAKE Designation: Review of Approved Drugs & Impact in Japan
This article reviews the PMDA SAKIGAKE Designation, highlighting approved drugs such as XYZ for cancer treatment and its significant impact on Japan's pharmaceutical landscape.
NMPA Conditional Approval Pathway: Accelerating Innovative Oncology Drug Access in China
The NMPA Conditional Approval Pathway is transforming access to innovative oncology drugs such as [Drug Name], expediting their availability for patients in China.
SAKIGAKE Designation Impact: Accelerating Rare Disease Drug Approvals in Japan
The SAKIGAKE Designation significantly speeds up the approval process for rare disease drugs in Japan, enhancing access to treatments like XYZ for patients with ABC condition.
NMPA Approval Trends 2024: Accelerated Approvals & Key Therapies in China
Discover the latest NMPA approval trends for 2024, focusing on accelerated approvals and significant therapies such as XYZ for cancer in China.
NMPA Accelerated Approval Oncology: 2027 Market Analysis & Case Studies
This article delves into NMPA's accelerated approval process for oncology, featuring a 2027 market analysis and insightful case studies on drug XYZ-123.
PMDA SAKIGAKE Designation: Expedited Approval & Market Impact in Japan
Explore the significance of PMDA SAKIGAKE Designation in expediting approval processes and its impact on the market for drugs like XYZ in Japan.
NMPA Accelerated Approval Oncology: Impact on Innovative Drug Market Access in China
This article examines the NMPA's accelerated approval process and its significant influence on the market access of innovative oncology drugs in China.
MorphoSys' MINJUVI (Tafasitamab) Approved in Australia for Relapsed/Refractory Follicular Lymphoma
Australia approves MINJUVI (tafasitamab) as first chemotherapy-free dual-targeted immunotherapy for relapsed/refractory follicular lymphoma patients.
Hengrui Pharma Q1 2026 Results: Anti-PD-L1/TGF-βRII Fusion Protein Approved in China
Hengrui Pharma reports Q1 2026 growth with three innovative drug approvals including breakthrough anti-PD-L1/TGF-βRII bi-functional fusion protein in China.